Bevacizumab and Vasoconstriction

Sponsor
Radboud University Medical Center
Study ID
NCT00929058
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - 50 Years
Healthy Volunteers
Accepted

Interventions

  • Bevacizumab — DRUG
    Intra-arterial infusion during 6 minutes

Study Details

Rationale: The introduction of angiogenesis inhibitors has remarkably improved treatment of patients with several types of cancer. One of the most common side effects of angiogenesis inhibitors is hypertension. In patients treated with bevacizumab hypertension had an overall incidence up to 32%. The etiology of hypertension caused by treatment with angiogenesis inhibitors is unclear. Objective: To study if arterial bevacizumab infusion causes acute vasoconstriction using plethysmography in healthy volunteers.

Key Dates

First listed
Jun 26, 2009
Start date
Jun 30, 2009
Status verified
Jun 2009
Primary completion
Nov 30, 2009
Completion
Nov 30, 2009

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP

Arms

  • Experimental: Bevacizumab

Primary Outcome Measure

Fore-arm vasomotor response to administered bevacizumab, expressed as percentage change in forearm blood flow ratio [ Time Frame: Infusion of bevacizumab during 6 minutes ]

Related Studies